Wealthfront Advisers
TXG icon

Wealthfront Advisers’s 10x Genomics TXG Stock Holding History

Wealthfront Advisers’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,380
Closed -$492K – 776
2021
Q3 		$492K Buy
3,380
+1,915
+131% +$329K ﹤0.01% 561
2021
Q2 		$287K Buy
+1,465
New +$265K ﹤0.01% 580

Other funds holding TXG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wealthfront Advisers's TXG Position: Q4 2021 in Review

Wealthfront Advisers sold out of 10x Genomics (TXG) in Q4 2021, closing a stake of 3,380 shares — an estimated $492K sold.

Wealthfront Advisers first reported a position in TXG in Q2 2021 and held it in 2 quarters. The position peaked at $492K in Q3 2021. 365 funds tracked by Wall St. Rank hold TXG as of Q4 2021.

  • Wealthfront Advisers reported no remaining 10x Genomics position as of Q4 2021 after selling out during the quarter.
  • Wealthfront Advisers sold 3,380 10x Genomics shares in Q4 2021, an estimated $492K.
  • Wealthfront Advisers first reported a position in 10x Genomics in Q2 2021 and held it in 2 quarters.
  • Wealthfront Advisers's 10x Genomics position peaked at $492K in Q3 2021.
  • 365 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2021.

Based on Wealthfront Advisers's 13F filing for Q4 2021, filed 21 Jan 2022.